NICE guidance on pazopanib for first-line treatment of advanced renal-cell carcinoma

被引：4
|
作者：
Griffiths, Christian [1 ]
Hay, Nicola [1 ]
Sutcliffe, Frances [1 ]
Stevens, Andrew [1 ]
机构：
[1] Natl Inst Hlth & Clin Excellence, Manchester, Lancs, England
来源：
LANCET ONCOLOGY | 2011年 / 12卷 / 03期
关键词：
INTERFERON ALPHA-2A; RANDOMIZED-TRIAL; MEDROXYPROGESTERONE; VINBLASTINE;
D O I：
10.1016/S1470-2045(11)70042-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：221 / 222
页数：2
相关论文
共 50 条
  • [31] SECOND-LINE TREATMENT WITH PAZOPANIB FOLLOWING FIRST-LINE SUNITINIB OR BEVACIZUMAB IN ADVANCED RENAL CELL CARCINOMA: PRELIMINARY RESULTS OF A PHASE II TRIAL
    Hainsworth, J.
    Spigel, D. R.
    Webb, C.
    Daniel, D.
    Friedman, E.
    Burris, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 285 - 285
  • [32] Treatment of Advanced Renal-Cell Carcinoma
    Huillard, Olivier
    Alexandre, Jerome
    Goldwasser, Francois
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (09): : 888 - 888
  • [33] Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma
    Chedgy, Edmund C. P.
    Black, Peter C.
    UROLOGY, 2016, 89 : 8 - 9
  • [34] Pazopanib or Sunitinib? cost-utility analysis of pazopanib versus sunitinib in the first-line treatment of metastatic renal cell carcinoma in Jordan
    Al-Rabayah, Abeer A.
    Sawalha, Razan
    Al Froukh, Rawan Fawzi
    Al-Bawab, Rand
    Jaddoua, Saad M.
    JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2021, 12 (04) : 566 - 573
  • [35] Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use
    Lyseng-Williamson K.A.
    Drugs & Therapy Perspectives, 2018, 34 (10) : 457 - 465
  • [36] Advanced Renal Cell Carcinoma Cabozantinib is a recommended Treatment Option for First-line Therapy
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (03) : 150 - 151
  • [37] NICE guidance on bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer
    Dyer, Matthew
    Richardson, Joanna
    Robertson, Janet
    Adam, Jane
    LANCET ONCOLOGY, 2013, 14 (08): : 689 - 690
  • [38] An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy
    Capri, Stefano
    Porta, Camillo
    Condorelli, Claudia
    Premoli, Eleonora
    Khare, Ankur
    Kalra, Manik
    Modi, Niraj
    Ratto, Barbara
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1579 - 1587
  • [39] COSTS ASSOCIATED WITH HEALTH CARE RESOURCE USE IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE TREATMENT WITH PAZOPANIB VERSUS SUNITINIB
    Hackshaw, M. D.
    Hansen, R. N.
    Nagar, S. P.
    Arondekar, B.
    Deen, K. C.
    Sullivan, S. D.
    Ramsey, S. D.
    VALUE IN HEALTH, 2014, 17 (03) : A77 - A78
  • [40] Pazopanib for the Treatment of Patients with Advanced Renal Cell Carcinoma
    Lang, Joshua M.
    Harrison, Michael R.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2010, 4 : 95 - 105
12345